Fernando Rogério Pavan

Prof. Dr. Fernando Rogério Pavan

Departamento de Ciências Biológicas, Universidade Estadual Paulista (UNESP), Sao Paulo 14801-902, Brazil
+1
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2010 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Fernando Rogério PavanFernando Rogério Pavan
Fernando Rogério Pavan
PMPedro Ivo da Silva Maia
Pedro Ivo da Silva Maia
SLSergio R.A. Leite
Sergio R.A. Leite
VDVictor M. Deflon
Victor M. Deflon
ABAlzir A. Batista
Alzir A. Batista
CLClarice Q.F. Leite
Clarice Q.F. Leite

1 December 2014 in Journal of Inorganic Biochemistry
Verified
Journal Article
Closed access
Isabel CorreiaIsabel Correia
Isabel Correia
PAPedro Adão
Pedro Adão
SRSomnath Roy
Somnath Roy
MWMohammed Ahmed Wahba
Mohammed Ahmed Wahba
CMCristina Matos
Cristina Matos
JPJoão da Costa Pessoa
João da Costa Pessoa

12 November 2024 in Advanced Science
Verified
Journal Article
Open access
Cesar Augusto Roque-BordaCesar Augusto Roque-Borda
Cesar Augusto Roque-Borda
LPLaura Maria Duran Gleriani Primo
Laura Maria Duran Gleriani Primo
KMKaila Petronila Medina-Alarcón
Kaila Petronila Medina-Alarcón
ICIsabella Cardeal Campos
Isabella Cardeal Campos
CNCamila de Fátima Nascimento
Camila de Fátima Nascimento
Fernando AlbericioFernando Albericio
Fernando Albericio
Polymicrobial biofilms adhere to surfaces and enhance pathogen resistance to conventional treatments, significantly contributing to chronic infections in the respiratory tract, oral cavity, chronic wounds, and on medical devices. This review examines antimicrobial peptides (AMPs) as a promising alternative to traditional antibiotics for treating biofilm‐associated infections. AMPs, which can be produced as part of the innate immune response or synthesized therapeutically, have broad‐spectrum antimicrobial activity, often disrupting microbial cell membranes and causing cell death. Many specifically target negatively charged bacterial membranes, unlike host cell membranes. Research shows AMPs effectively inhibit and disrupt polymicrobial biofilms and can enhance conventional antibiotics' efficacy. Preclinical and clinical research is advancing, with animal studies and clinical trials showing promise against multidrug‐resistant bacteria and fungi. Numerous patents indicate increasing interest in AMPs. However, challenges such as peptide stability, potential cytotoxicity, and high production costs must be addressed. Ongoing research focuses on optimizing AMP structures, enhancing stability, and developing cost‐effective production methods. In summary, AMPs offer a novel approach to combating biofilm‐associated infections, with their unique mechanisms and synergistic potential with existing antibiotics positioning them as promising candidates for future treatments.

1 April 2010 in Phytomedicine
Verified
Journal Article
Closed access
NHN.K. Honda
N.K. Honda
Fernando Rogério PavanFernando Rogério Pavan
Fernando Rogério Pavan
RCR.G. Coelho
R.G. Coelho
SLS.R. de Andrade Leite
S.R. de Andrade Leite
AMANA CAMILA MICHELETTI
ANA CAMILA MICHELETTI
CLC.Q.F. Leite
C.Q.F. Leite

15 March 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JPJanaína Pontes
Janaína Pontes
ABAnna Beatriz Toledo Borges
Anna Beatriz Toledo Borges
Cesar Augusto Roque-BordaCesar Augusto Roque-Borda
Cesar Augusto Roque-Borda
Fernando Rogério PavanFernando Rogério Pavan
Fernando Rogério Pavan
Bacterial resistance is an emergency public health problem worldwide, compounded by the ability of bacteria to form biofilms, mainly in seriously ill hospitalized patients. The World Health Organization has published a list of priority bacteria that should be studied and, in turn, has encouraged the development of new drugs. Herein, we explain the importance of studying new molecules such as antimicrobial peptides (AMPs) with potential against multi-drug resistant (MDR) and extensively drug-resistant (XDR) bacteria and focus on the inhibition of biofilm formation. This review describes the main causes of antimicrobial resistance and biofilm formation, as well as the main and potential AMP applications against these bacteria. Our results suggest that the new biomacromolecules to be discovered and studied should focus on this group of dangerous and highly infectious bacteria. Alternative molecules such as AMPs could contribute to eradicating biofilm proliferation by MDR/XDR bacteria; this is a challenging undertaking with promising prospects.
2

1 February 2009 in Polyhedron
Verified
Journal Article
Closed access
PMPedro Ivo da Silva Maia
Pedro Ivo da Silva Maia
Fernando Rogério PavanFernando Rogério Pavan
Fernando Rogério Pavan
CLClarice Q.F. Leite
Clarice Q.F. Leite
SLSebastião S. Lemos
Sebastião S. Lemos
GSGerimário F. de Sousa
Gerimário F. de Sousa
VDVictor M. Deflon
Victor M. Deflon